The FDA is set to decide whether to approve AstraZeneca’s HER2-targeting antibody-drug conjugate in the second quarter of next year. AstraZeneca landed the PDUFA date for [fam-] trastuzumab deruxtecan after the FDA accepted its approval submission for priority review.
